BEVACIZUMAB AND FOTEMUSTINE AS SALVAGE THERAPY IN RECURRENT GLIOBLASTOMA: A PHASE II MULTICENTER ITALIAN STUDY

被引：0
|
作者：
Trevisan, E. [1 ]
Ruda, R. [1 ]
Picco, E. [1 ]
Crasto, S. Greco [2 ]
Caroli, M. [3 ]
Fabrini, A. [4 ]
Scotti, V. [4 ]
Lolli, I.
Guarneri, D. [1 ]
Soffietti, R. [1 ]
机构：
[1] Neurooncol Dept, Turin, Italy
[2] Dept Radiol, Turin, Italy
[3] Dept Neurosurg, Turin, Italy
[4] Dept Radiotherapy, Pisa, Italy
来源：
NEURO-ONCOLOGY | 2010年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：49 / 50
页数：2
相关论文
共 50 条
  • [31] A PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH FOTEMUSTINE IN RECURRENT ANAPLASTIC GLIOMAS
    Soffietti, Riccardo
    Magistrello, Michela
    Bertero, Luca
    Bosa, Chiara
    Crasto, Stefania Greco
    Garbossa, Diego
    Lolli, Ivan
    Trevisan, Elisa
    Ruda, Roberta
    NEURO-ONCOLOGY, 2012, 14 : 71 - 71
  • [32] Alternative schedule of Fotemustine in elderly patients with recurrent glioblastoma: a phase II prospective study
    Bellu, L.
    Lombardi, G.
    Pambuku, A.
    Bergo, E.
    Vittorina, Z.
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 144
  • [33] Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab na⟨ve, recurrent glioblastoma
    Reardon, David A.
    Desjardins, Annick
    Peters, Katherine B.
    Gururangan, Sridharan
    Sampson, John H.
    McLendon, Roger E.
    Herndon, James E., II
    Bulusu, Anuradha
    Threatt, Stevie
    Friedman, Allan H.
    Vredenburgh, James J.
    Friedman, Henry S.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 107 (01) : 155 - 164
  • [34] Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
    David A. Reardon
    Annick Desjardins
    Katherine B. Peters
    Sridharan Gururangan
    John H. Sampson
    Roger E. McLendon
    James E. Herndon
    Anuradha Bulusu
    Stevie Threatt
    Allan H. Friedman
    James J. Vredenburgh
    Henry S. Friedman
    Journal of Neuro-Oncology, 2012, 107 : 155 - 164
  • [35] Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study
    Fabi, Alessandra
    Metro, Giulio
    Vidiri, Antonello
    Lanzetta, Gaetano
    Carosi, Mariantonia
    Telera, Stefano
    Maschio, Marta
    Russillo, Michelangelo
    Sperduti, Isabella
    Carapella, Carmine M.
    Cognetti, Francesco
    Pace, Andrea
    JOURNAL OF NEURO-ONCOLOGY, 2010, 100 (02) : 209 - 215
  • [36] Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study
    Alessandra Fabi
    Giulio Metro
    Antonello Vidiri
    Gaetano Lanzetta
    Mariantonia Carosi
    Stefano Telera
    Marta Maschio
    Michelangelo Russillo
    Isabella Sperduti
    Carmine M. Carapella
    Francesco Cognetti
    Andrea Pace
    Journal of Neuro-Oncology, 2010, 100 : 209 - 215
  • [37] Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme
    Sathornsumetee, S.
    Vredenburgh, J. J.
    Rich, J. N.
    Desjardins, A.
    Quinn, J. A.
    Mathe, A. E.
    Gururangan, S.
    Friedman, A. H.
    Friedman, H. S.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Reardon, David A.
    Sathornsumetee, Sith
    Vredenburgh, James J.
    Rich, Jeremy N.
    Desjardins, Annick
    Quinn, Jennifer A.
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allen H.
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2009, 11 (02) : 231 - 231
  • [39] A phase II study of subcutaneous bevacizumab for recurrent glioblastoma: Roadblocks and promises
    Quillin, Joseph
    Read, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Low-dose Fotemustine in elderly patients with recurrent glioblastoma: A phase II prospective study
    Bellu, L.
    Lombardi, G.
    Pambuku, A.
    Bergo, E.
    Zagonel, V.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S591 - S591
12345